Movement Alert｜Alibaba Health Rises 3.04% in Regular Trading, Innovative Drug Launch Platform Effect Continues to Intensify

Market Focus

Jul 06

On July 6, Alibaba Health rose 3.04% in regular trading, trading at HK$3.4/share, with turnover of HK$63.25 million, extending its recent upward momentum.

On the news front, the company's innovative drug launch platform effect continues to gain traction. On June 29, Hengrui Medicine's Class 1 innovative drug Ruiming (China's first self-developed highly selective URAT1 inhibitor for gout) and Yangtze River Pharmaceuticals' Class 1 new drug Taitoto (a next-generation PDE5 inhibitor for erectile dysfunction) both launched exclusively on Alibaba Health. On July 1, Jiudian Pharmaceutical's Jiuyue Loxoprofen Sodium Gel Patch also chose Alibaba Health for its nationwide online debut. The intensive onboarding of multiple innovative drugs reinforces the company's positioning as a premier online launch channel for new and specialty pharmaceuticals, validating its commercial value and digital service capabilities in the innovative drug commercialization chain. Management has previously guided FY2027 revenue growth of 10% to 15%, with innovative drug categories identified as the core growth driver.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1106101955"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106101955\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106101955?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106101955","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Alibaba Health Rises 3.04% in Regular Trading, Innovative Drug Launch Platform Effect Continues to Intensify","media":"Market Focus","content":"<p><p>On July 6, Alibaba Health rose 3.04% in regular trading, trading at HK$3.4/share, with turnover of HK$63.25 million, extending its recent upward momentum.</p><p>On the news front, the company's innovative drug launch platform effect continues to gain traction. On June 29, Hengrui Medicine's Class 1 innovative drug Ruiming (China's first self-developed highly selective URAT1 inhibitor for gout) and Yangtze River Pharmaceuticals' Class 1 new drug Taitoto (a next-generation PDE5 inhibitor for erectile dysfunction) both launched exclusively on Alibaba Health. On July 1, Jiudian Pharmaceutical's Jiuyue Loxoprofen Sodium Gel Patch also chose Alibaba Health for its nationwide online debut. The intensive onboarding of multiple innovative drugs reinforces the company's positioning as a premier online launch channel for new and specialty pharmaceuticals, validating its commercial value and digital service capabilities in the innovative drug commercialization chain. Management has previously guided FY2027 revenue growth of 10% to 15%, with innovative drug categories identified as the core growth driver.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Alibaba Health Rises 3.04% in Regular Trading, Innovative Drug Launch Platform Effect Continues to Intensify</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Alibaba Health Rises 3.04% in Regular Trading, Innovative Drug Launch Platform Effect Continues to Intensify\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-06 10:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 6, Alibaba Health rose 3.04% in regular trading, trading at HK$3.4/share, with turnover of HK$63.25 million, extending its recent upward momentum.</p><p>On the news front, the company's innovative drug launch platform effect continues to gain traction. On June 29, Hengrui Medicine's Class 1 innovative drug Ruiming (China's first self-developed highly selective URAT1 inhibitor for gout) and Yangtze River Pharmaceuticals' Class 1 new drug Taitoto (a next-generation PDE5 inhibitor for erectile dysfunction) both launched exclusively on Alibaba Health. On July 1, Jiudian Pharmaceutical's Jiuyue Loxoprofen Sodium Gel Patch also chose Alibaba Health for its nationwide online debut. The intensive onboarding of multiple innovative drugs reinforces the company's positioning as a premier online launch channel for new and specialty pharmaceuticals, validating its commercial value and digital service capabilities in the innovative drug commercialization chain. Management has previously guided FY2027 revenue growth of 10% to 15%, with innovative drug categories identified as the core growth driver.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00241","symbol_name":"阿里健康","start_time":0,"source_url":"","article_id":"1106101955","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106101955","pubTimestamp":1783303725,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 6, Alibaba Health rose 3.04% in regular trading, trading at HK$3.4/share, with turnover of HK$63.25 million, extending its recent upward momentum.On the news front, the company's innovative...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00241":"阿里健康"},"translate_title":"动感快讯|阿里巴巴-SW健康常规交易涨3.04%创新药首发平台效应持续加剧","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00241":1},"content_text":"On July 6, Alibaba Health rose 3.04% in regular trading, trading at HK$3.4/share, with turnover of HK$63.25 million, extending its recent upward momentum.On the news front, the company's innovative drug launch platform effect continues to gain traction. On June 29, Hengrui Medicine's Class 1 innovative drug Ruiming (China's first self-developed highly selective URAT1 inhibitor for gout) and Yangtze River Pharmaceuticals' Class 1 new drug Taitoto (a next-generation PDE5 inhibitor for erectile dysfunction) both launched exclusively on Alibaba Health. On July 1, Jiudian Pharmaceutical's Jiuyue Loxoprofen Sodium Gel Patch also chose Alibaba Health for its nationwide online debut. The intensive onboarding of multiple innovative drugs reinforces the company's positioning as a premier online launch channel for new and specialty pharmaceuticals, validating its commercial value and digital service capabilities in the innovative drug commercialization chain. Management has previously guided FY2027 revenue growth of 10% to 15%, with innovative drug categories identified as the core growth driver.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}